Related Experiment Video
Updated: Oct 30, 2025

Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique
Published on: September 23, 2022
Similarities and Differences Between COVID-19-Related Multisystem Inflammatory Syndrome in Children and Kawasaki
Min-Sheng Lee1, Yi-Ching Liu2, Ching-Chung Tsai3,4
1Division of Pediatric Infectious Disease, Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Insights
Multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 presents symptoms similar to Kawasaki disease (KD). This review clarifies the distinctions between MIS-C and KD to aid pediatricians in diagnosis.
Area of Science:
- Pediatrics
- Infectious Diseases
- Rheumatology
Background:
- COVID-19 has caused millions of deaths globally, with a lower mortality rate in children compared to adults.
- An emerging multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 has been reported, primarily in Europe and the US.
- MIS-C shares clinical and laboratory similarities with Kawasaki disease (KD), KD shock syndrome, and toxic shock syndrome.
Purpose of the Study:
- To differentiate between MIS-C and KD.
- To increase pediatrician awareness of MIS-C.
- To guide pediatricians in the differential diagnosis of MIS-C and KD.
Main Methods:
- This narrative review discusses the clinical features and laboratory characteristics of MIS-C.
- The review compares and contrasts MIS-C with Kawasaki disease.
- The focus is on identifying distinct features to aid in diagnosis.
Main Results:
- MIS-C exhibits distinct clinical and laboratory features that differentiate it from KD.
- While sharing similarities, MIS-C is not identical to KD.
- The review highlights key differences crucial for accurate diagnosis.
Conclusions:
- MIS-C is a distinct condition characterized by multisystem inflammation in children following COVID-19 infection.
- Distinguishing MIS-C from KD is essential for appropriate pediatric patient management.
- Increased awareness and understanding of MIS-C's unique characteristics will improve diagnostic accuracy.
Abstract:
In December 2019, the first case of coronavirus disease (COVID-19) was first reported in Wuhan, China. As of March 2021, there were more than 120 million confirmed cases of COVID-19 and 2.7 million deaths. The COVID-19 mortality rate in adults is around 1-5%, and only a small proportion of children requires hospitalization and intensive care. Recently, an increasing number of COVID-19 cases in children have been associated with a new multisystem inflammatory syndrome. Its clinical features and laboratory characteristics are similar to those of Kawasaki disease (KD), KD shock syndrome, and toxic shock syndrome. However, this new disorder has some distinct clinical features and laboratory characteristics. This condition, also known as multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19, has been observed mostly in Europe and the United States. This emerging phenomenon has raised the question of whether this disorder is KD triggered by SARS-CoV-2 or a syndrome characterized by multisystem inflammation that mimics KD. This narrative review is to discuss the differences between MIS-C and KD with the aim of increasing pediatricians' awareness of this new condition and guide them in the process of differential diagnosis.
Related Concept Videos
Myocarditis II: Clinical Features and Diagnostic Tests
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Endocarditis II: Clinical Features of Infective Endocarditis
Rheumatic Heart Disease I: Introduction
Myocarditis I: Introduction
Pericarditis II: Clinical Features and Diagnostic Tests

